Discovery Program Sample Clauses

Discovery Program. The objective of the Parties during the Discovery Program is for Regeneron to discover, identify and/or validate Targets from which to select Program Targets, generate Antibodies, including MTCs, against such Program Targets (including Program Targets that are Sanofi Targets) from which to select Lead Candidates, and develop them through IND Preparation to offer to Sanofi for joint development and commercialization under the terms set forth herein and in the License and Collaboration Agreement. During the first five (5) years of the Discovery Program, Regeneron will use Commercially Reasonable Efforts (i) to discover, identify and validate Targets and (ii) to select Program Targets for review and discussion by the JRC pursuant to Section 3.1 herein. ****************************************. Regeneron will use Commercially Reasonable Efforts to manufacture preclinical and clinical supplies of the Lead Candidates and Product Candidates for the Discovery Program and the Phase 1 Clinical Trial. The JRC will prioritize the Antibodies, including MTCs, to be further pursued as Lead Candidates, and Regeneron will commence IND Preparation activities only for those Antibodies, including MTCs, that meet the applicable criteria set forth in Schedule 1.42. The JRC will evaluate, select and prioritize Targets for the Target List. However, Regeneron will have the right to conduct Target discovery and validation on Targets as part of the Discovery Program before they are formally approved by the JRC for selection on the Target List but shall notify the JRC of any new Target at the next meeting of the JRC. Subject to Sanofi’s selection rights under Section 3.1(e) and the other terms of this Agreement, Regeneron will have sole responsibility for the design and conduct of all activities under the Discovery Program, including, without limitation, decisions relating to initiation and termination of programs and activities, manufacturing activities, and staffing and resource allocation between different programs and activities in the Discovery Program. Sanofi, through the JRC, will provide consultation and advice to support Regeneron’s efforts.
AutoNDA by SimpleDocs
Discovery Program. During the Option Term, Agios shall be responsible for conducting discovery research activities with the principal goals of (i) identifying and validating Collaboration Targets in accordance with the Validation Criteria, (ii) identifying and discovering Collaboration Compounds that either activate or inhibit through direct binding to a Collaboration Target, (iii) nominating Development Candidates, and (iv) characterizing, optimizing and supporting the pre-clinical Development of Development Candidates, including IND-Enabling Studies; provided that, if Celgene and Agios both consent, Celgene may also be assigned responsibility for some of the foregoing discovery research activities at Agios’ sole expense.
Discovery Program. Future Fellowships Grant Details C1 Purpose of the Grant
Discovery Program. During the Discovery Term, Alnylam shall use Commercially Reasonable Efforts to Discover [**] RNAi Therapeutics directed to JCV that meet the Development Criteria agreed upon by the JSC and included in the Annual Work Plan (the "Discovery Program"). Alnylam shall from time to time notify the JSC in writing that it believes that a particular RNAi Therapeutic directed to JCV Discovered by Alnylam meets the Development Criteria. Upon such notice, the JSC will promptly meet and Alnylam shall provide the JSC with the data and information in its possession and Control regarding the applicable RNAi Therapeutic. Alnylam shall present Biogen Idec with [**] RNAi Therapeutics in accordance with this Section 2.2. Biogen Idec shall have the right to select [**] RNAi Therapeutics presented by Alnylam by written notice to Alnylam. Biogen Idec may make its selection [**] at any time after Alnylam's presentation of the first RNAi Therapeutic to the JSC, but Biogen Idec must identify [**] no later than [**] days after Alnylam's presentation of [**] to the JSC. For avoidance of doubt, if Biogen Idec selects [**] prior to Alnylam's presentation of [**] to the JSC, Alnylam will not be relieved of its obligation to present [**] to the JSC. In the event that Biogen Idec wishes to [**], Biogen Idec shall do so by written notice to Alnylam no later than [**] days after Alnylam's presentation to the JSC of [**].
Discovery Program. During the Option Term, Array shall be responsible for conducting a discovery research program (the “Discovery Program”).
Discovery Program. SELECTED QTS
Discovery Program. ARTICLE 3
AutoNDA by SimpleDocs
Discovery Program. 3.1.1 During the period beginning on the New Effective date and thereafter for the remainder of the Discovery Program Period, subject to the terms and conditions of this Agreement, Licensee shall pay [***] in research and development funding to Penn to fund the Discovery Program (“Discovery Support Amount”). Such Discovery Support Amount shall be inclusive of Penn’s standard indirect charges. Licensee shall remit such funds in each Discovery Program Year of the Discovery Program Period in accordance with Section 3.2.1 below and such funds will be allocated and utilized solely to support the Discovery Program as set forth in the Discovery Plan. [***].
Discovery Program. During the Option Term, Array and, if directed by the JRC, JDC or JMC and expressly agreed by Celgene in writing, Celgene shall be responsible for conducting a discovery research program with the principal goals of: (i) identifying and discovering Compounds that directly modulate each of the Targets; (ii) characterizing, optimizing and supporting the pre-clinical development of such Compounds; (iii) conducting a Phase I clinical trial and, where applicable under Section 3.7.3 below, a Phase II clinical trial with respect to Compounds that have been designated as Development Compounds pursuant to Section 3.5 below; and (iv) if required pursuant to Section 3.7.4 below, conducting continued preclinical development and potentially a Phase I clinical trial with respect to certain Development Back-Up Compounds (“Discovery Program”). During the Option Term, Array shall, on a Target-by-Target basis, use Diligent Efforts to conduct the Discovery Program with respect to such Target.
Discovery Program. 2.1 Discovery Program 11 2.2 Term of the Discovery Program 12 2.3 Discovery Plans 12 2.4 Target List 13 2.5 Commercially Reasonable Efforts; Compliance with Laws 14 2.6 Exchange of Information 15 2.7 Further Assurances and Transaction Approvals 15 2.8 Exclusive Discovery Program 15 2.9 Tail Period 18 2.10 Research Licenses; Licenses Generally 18 2.11 Immunoconjugates 18 2.12 Sanofi Target Licenses 18 2.13 Non-Exclusive License to Sanofi 18 2.14 Invention Assignment 19 2.15 Supply of VelociGene® Mice 19 2.16 Option for VelocImmune License 19 2.17 Option for Additional Technologies 19 2.18 Third Party Platform Licenses 19 ARTICLE 3 JOINT RESEARCH COMMITTEE 3.1 The Joint Research Committee 19 3.2 Alliance Management 21 3.3 Resolution of Governance Matters 21 3.4 Obligations of the Parties and their Affiliates 22 ARTICLE 4
Time is Money Join Law Insider Premium to draft better contracts faster.